scholarly journals Measurement of plasma fibrinogen and D-dimer in a sample of Iraqi patients with solid malignant tumors

2020 ◽  
Vol 16 (2) ◽  
pp. 21-24
Author(s):  
Maysaa Awadh Bahaaldeen ◽  
Haithem Ahmed Al-Rubaie ◽  
Ali Almothaffar
Keyword(s):  
Laboratory Tests ◽  
Fibrinogen Level ◽  
Malignant Tumors ◽  
Plasma Fibrinogen ◽  
Control Group ◽  
P Value ◽  
Plasma Fibrinogen Level ◽  
Medical City ◽  
D Dimer ◽  
Solid Malignant Tumors

Background: Multifactor affect the pathogenesis of thrombosis in solid malignancy; however, a significant role is attributed to the cancer cells ability to interact with and activate the host hemostatic system. [1]  Hemostasis is highly correlated to tumor growth, angiogenesis and metastasis, modulation of these pathways reflects interesting and promising treatment options in the future. [1] Most patients with cancer frequently suffer from chronic compensated DIC and have abnormal laboratory coagulation tests without clinical manifestations of thrombosis, which is a subclinical hypercoagulable state that can be detected by varying degrees of activation of blood clotting. The results of laboratory tests in these patients reflect continuous fibrin formation and lysis during the course of malignancy. [1] Aim of study: To study the effect of solid malignant tumors on blood coagulation via measurements of plasma fibrinogen and D-dimer. Subjects and methods: Thirty patients (9 males and 21 females) attending the oncology consultatory out-patient clinic at Baghdad Teaching Hospital/ Medical City were randomly selected and included in this study. These patients were newly diagnosed as having malignant solid tumors depending on histopathological reports from private and governmental sectors. All the laboratory tests were done at the hematology and biochemistry departments of Teaching Laboratories/ Medical City. Results: Plasma fibrinogen level was significantly higher in patients group rather than control group (3.863 ±0.706) Vs (2.497±0.457 g/L} respectively, (P-value 0.001).The mean value of factor VIII activity was {181% ±58.4)and (99.3% ±11.1)for patient and control groups respectively, the P-Value was significant ( > 0.001 ).D-dimer was negative for all members of control group, for patients group ( 66.7 %) of them showed positive D-dimer and (33.3)were negative for D-dimer ,P-value was significant ( >0.001 ). Conclusions: There was increase in plasma fibrinogen level and positive D-dimer in cancer patients compared to the control group reflecting subclinical thrombophilia and higher risk of VTE in patients with solid tumors due to activation of prothrombotic and fibrinolytic pathways by malignant cells which is vital for the use of primary prophylaxis by anticoagulants.

scholarly journals Plasma Fibrinogen as a Biomarker of Stable and Exacerbated Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 11 (1) ◽  
pp. 48-53
Author(s):  
Kashifa Ehsan ◽  
Sibgha Zulfiqar ◽  
Amber Hassan ◽  
Humaira Waseem
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Control Group ◽  
Chronic Obstructive ◽  
P Value ◽  
Plasma Fibrinogen Level ◽  
Obstructive Pulmonary Disease ◽  
Lung Functions

Study Design: An experimental, comparative, cross-sectional study Place and Duration of Study: Department of Physiology, Federal Post Graduate Medical Institute (FPGMI), Sheikh Zayed Medical Complex Lahore, Pakistan from August 2013 to 2014 Background: Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease, but is a partially reversible chronic inflammatory condition characterized by airway obstruction. COPD remains under-diagnosed and under-treated because the only available diagnostic method at present is testing lung functions by spirometry which is not helpful to determine the severity and clinical outcomes of the disease. Circulating biomarkers are under consideration for various diseases worldwide. Plasma fibrinogen is emerging as one of the most promising biomarkers of COPD in smokers. Objective: The objective of this study is to investigate if plasma fibrinogen can serve as a diagnostic biomarker of COPD in smokers, and if its further higher levels are seen in the exacerbated state of the disease in comparison to the stable disease. Materials and Methods: 75 middle-aged to old-age smokers of either gender were selected. Lung functions of every participant were measured to determine Forced Expiratory Volume in the first second (FEV1), Forced Vital Capacity (FVC), and the ratio of FEV1/FVC by spirometry. On the basis of the results of the tests, subjects were divided into three groups; firstly, the control group of chronic smokers without COPD, secondly, smokers with COPD in a stable state, and thirdly, patients in an exacerbated state of COPD. Plasma fibrinogen was quantitatively estimated in every individual of all three groups by the Clauss method using the Hemostat Fibrinogen kit. Results: The average Plasma fibrinogen level was found to be 235.008 mg/dl in healthy smokers (control group), while an average of 440.12mg/dl was measured in patients with stable COPD. The difference in plasma fibrinogen levels was found to be significant, having a p-value of (0.000). In the third group with declined lung function predicting acute exacerbated COPD, fibrinogen was found to be > 453.2 mg/dl, which was significantly higher than in the stable disease group (p-value > 0.0017) Conclusion: Plasma fibrinogen level measurement is a reliable and accessible test in terms of a diagnostic marker of COPD, as compared to conventional lung function testing done in the past.

scholarly journals Investigate of Haemostatic and Fibrinolytic System Parameters among Sickle Cell Anaemia Patients in the Khartoum State

2020 ◽  
Vol 8 (02) ◽  
pp. 01-05
Author(s):  
Elteleb G. Elnaim ◽  
Samar Ibrahim ◽  
Duaa Ahmed ◽  
Rayan Aldaw ◽  
Nagwa Salih ◽  
...  
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anaemia ◽  
Fibrinogen Level ◽  
Fibrinolytic System ◽  
Control Group ◽  
P Value ◽  
Study Group ◽  
System Parameters ◽  
And Control ◽  
D Dimer

Introduction: A sickle cell anaemia one of a haemoglobinopathy, which constituted as a model for genetically inherited disorders, the course of the disease involves may crises, the investigation of hemostatic components as fibrinogen and fibrinolysis as D-dimer, reflect the overall hemostatic status in the sickle cell anaemia patients. Aim: To investigates hemostatic and fibrinolytic system parameters among sickle cell anaemia patients in the Khartoum state. Methods: The study was conducted in Khartoum state, in JafarIbn Auf Reference Hospital for children as descriptive case-control, a laboratory-based study from 2017-18, specimens were collected randomly of the study population with irrespective to age and gender, blood draw in tri-sodium citrate container, the ethical and consent were obtained. The fibrinogen level was estimated by CA51 semi-automated coagulation analyzer optically based, and the D-dimer were assayed by MISPA-i2, a nephelometric based, the results for each parameter were recorded and using statistical package for the social sciences (SPSS) software for analysis by independent T-test and the statistical significance > 0.05. Results: A hundred participants fifty as study group (HbSS) sickle cell anemic Sudanese child clinically and laboratory-confirmed and fifty healthy as the control group, in comparing a mean of fibrinogen show statistically insignificant (P value 0.645) study group 291.1 ± 107.8 mg/dL and control group 283.4 ± 49.1 mg/dL, but there was a significant difference in comparing a mean of D-dimer in study group 0.56 ± 0.33 μg/mL and control group 0.33 ± 0.14 the P. value 0.00015. Conclusion: The level of D-dimer may be used as a hypercoagulability biomarker in comparison to the level of fibrinogen level for sickle cell anaemia Sudanese child.

Platelet Adhesiveness and Fibrinolysis after Recent Cerebro-Vascular Accidents and their Relationship with Subsequent Deep Venous Thrombosis of the Legs

1976 ◽  
Vol 36 (01) ◽  
pp. 127-132 ◽  
Author(s):  
C. P Warlow ◽  
J. A. N Rennie ◽  
D Ogston ◽  
A. S Douglas
Keyword(s):  
Platelet Count ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Plasminogen Activator ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Platelet Adhesiveness ◽  
Plasma Fibrinogen Level ◽  
Vascular Accidents ◽  
Subsequent Rise

SummaryIn fifteen patients with a cerebro-vascular accident resulting in an acute hemiplegia there was a subsequent rise in the platelet count and plasma fibrinogen level. There were no significant alterations in platelet adhesiveness, plasminogen activator, plasminogen, FR-antigen and haematocrit. Patients diagnosed as developing deep venous thrombosis with the 125I-fibrinogen technique had a significantly lower platelet adhesiveness and plasminogen level than those who were not.

Variation in the Promoter Region of the β Fibrinogen Gene Is Associated with Plasma Fibrinogen Levels in Smokers and Non-Smokers

1991 ◽  
Vol 65 (05) ◽  
pp. 487-490 ◽  
Author(s):  
A E Thomas ◽  
F R Green ◽  
C H Kelleher ◽  
H C Wilkes ◽  
P J Brennan ◽  
...  
Keyword(s):  
Heart Disease ◽  
Promoter Region ◽  
Fragment Length Polymorphism ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Healthy Men ◽  
History Of ◽  
General Practices ◽  
Restriction Fragment Length

SummaryWe investigated the association between fibrinogen levels and a HaeIII restriction fragment length polymorphism located at −453 bp from the start of transcription of the β fibrinogen gene. 292 healthy men aged 45 to 69 years, recruited from general practices throughout Britain, were studied. None had a history of ischaemic heart disease. 41.1% (120) were smokers and fibrinogen levels were higher in this group. The frequency of the noncutting allele (designated H2) was 0.19 and was the same in smokers and non-smokers. The H2 allele was associated with elevated levels of fibrinogen in both smokers and non-smokers and the effect of genotype was similar in both groups. After smoking, HaeIII genotype was the strongest predictor of fibrinogen levels and explained 3.1% of the variance in fibrinogen levels. These results confirm earlier studies that variation at the fibrinogen locus contributes to the between-individual differences in plasma fibrinogen level.

A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants

1992 ◽  
Vol 68 (03) ◽  
pp. 261-263 ◽  
Author(s):  
A K Banerjee ◽  
J Pearson ◽  
E L Gilliland ◽  
D Goss ◽  
J D Lewis ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intermittent Claudication ◽  
Fibrinogen Level ◽  
Past History ◽  
Fold Increase ◽  
Arterial Disease ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Factors Associated ◽  
Probability Of Death

SummaryA total of 333 patients with stable intermittent claudication at recruitment were followed up for 6 years to determine risk factors associated with subsequent mortality. Cardiovascular diseases were the underlying cause of death in 78% of the 114 patients who died. The strongest independent predictor of death during the follow-up period was the plasma fibrinogen level, an increase of 1 g/l being associated with a nearly two-fold increase in the probability of death within the next 6 years. Age, low ankle/brachial pressure index and a past history of myocardial infarction also increased the probability of death during the study period. The plasma fibrinogen level is a valuable index of those patients with stable intermittent claudication at high risk of early mortality. The results also provide further evidence for the involvement of fibrinogen in the pathogenesis of arterial disease.

scholarly journals An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients

The Breast ◽  
2015 ◽  
Vol 24 (5) ◽  
pp. 667-672 ◽  
Author(s):  
Sabine Krenn-Pilko ◽  
Uwe Langsenlehner ◽  
Tatjana Stojakovic ◽  
Martin Pichler ◽  
Armin Gerger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Breast Cancer Patients ◽  
Disease Specific

scholarly journals A prospective, open label, randomized-controlled study to evaluate the efficacy and safety of Herbovir syrup in mildly symptomatic COVID-19 patients

2020 ◽  
Vol 10 (1) ◽  
pp. 106
Author(s):  
A. Gopal Rao ◽  
Shankar Achar Somashekar ◽  
Poorna Prasad ◽  
Manjunath Reddy Lekkala ◽  
Sreenivasa Hanumanthaiah ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Standard Of Care ◽  
Pulmonary Complications ◽  
Controlled Study ◽  
Control Group ◽  
P Value ◽  
Immune Markers ◽  
Open Label ◽  
Early Recovery ◽  
D Dimer

Background: COVID-19 patients experience cytokine storm which cause pulmonary and extra-pulmonary complications. Effective antiviral and immune boosters are need of hour to treat COVID-19 as well as post COVID complications.Methods: In this study involving mild COVID-19 we randomized 40 patients to receive a Herbovir syrup along with standard of care (SOC) or SOC alone in 1:1 ratio. We evaluated the benefits of Herbovir syrup by assessing clinical outcomes and improvement in immune markers (LDH, CRP, D-dimer).Results: At the end of the study the immune markers in Herbovir group improved significant compared to control group. In patients who received Herbovir, LDH decreased from 334 U/l at baseline to 254 U/l at the end of treatment (p value <0.009), CRP decreased from 7.4 mg/l to 3.1 mg/l (p value=0.0171) and D-dimer decreased from 0.610 mg/l at baseline to 318 mg/l at the end of study (p value=0.001). TLC values did not go below normal range in Herbovir group whereas 8 patients in control group had low TLC at the end of study. Early recovery from COVID 19 symptoms was observed in >75% patients in Herbovir treated group.Conclusions: Herbovir accelerated recovery of COVID-19 patients by early improvement in clinical symptoms and immune markers in this study and results clearly indicates that Herbovir syrup has antiviral, immune booster activity and has definitive role in the management of mild COVID-19 patients along with standard of care. (Funded by Venkat pharma. CTRI no. CTRI/2020/08/027041).

Sign in / Sign up

Export Citation Format

Share Document